Janson ET - Search Results

1

Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.

Janson ET, Knigge U, Dam G, Federspiel B, Grønbaek H, Stålberg P, Langer SW, Kjaer A, Arola J, Schalin-Jäntti C, Sundin A, Welin S, Thiis-Evensen E, Sorbye H. Janson ET, et al. Acta Oncol. 2021 Jul;60(7):931-941. doi: 10.1080/0284186X.2021.1921262. Epub 2021 May 17. Acta Oncol. 2021. PMID: 33999752

2

The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors.

Oberg K, Eriksson B, Janson ET. Oberg K, et al. Among authors: janson et. Ann N Y Acad Sci. 1994 Sep 15;733:471-8. doi: 10.1111/j.1749-6632.1994.tb17297.x. Ann N Y Acad Sci. 1994. PMID: 7978897 Review. No abstract available.

3

Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial.

Janson ET, Kauppinen HL, Oberg K. Janson ET, et al. Acta Oncol. 1993;32(2):231-3. doi: 10.3109/02841869309083917. Acta Oncol. 1993. PMID: 8323762 Clinical Trial.

4

Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.

Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K. Imam H, et al. Among authors: janson et. Acta Oncol. 1997;36(6):607-14. doi: 10.3109/02841869709001323. Acta Oncol. 1997. PMID: 9408151

5

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.

Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Fjällskog ML, et al. Among authors: janson et. Cancer. 2001 Sep 1;92(5):1101-7. doi: 10.1002/1097-0142(20010901)92:5<1101::aid-cncr1426>3.0.co;2-v. Cancer. 2001. PMID: 11571721 Clinical Trial.

6

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.

Fjällskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B. Fjällskog ML, et al. Among authors: janson et. Med Oncol. 2002;19(1):35-42. doi: 10.1385/MO:19:1:35. Med Oncol. 2002. PMID: 12025889

7

Octreoscan in patients with bronchial carcinoid tumours.

Granberg D, Sundin A, Janson ET, Oberg K, Skogseid B, Westlin JE. Granberg D, et al. Among authors: janson et. Clin Endocrinol (Oxf). 2003 Dec;59(6):793-9. doi: 10.1046/j.1365-2265.2003.01931.x. Clin Endocrinol (Oxf). 2003. PMID: 14974924

8

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours.

Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE, Eriksson BK. Welin SV, et al. Among authors: janson et. Eur J Endocrinol. 2004 Jul;151(1):107-12. doi: 10.1530/eje.0.1510107. Eur J Endocrinol. 2004. PMID: 15248829 Clinical Trial.

9

Malignant gastric ghrelinoma with hyperghrelinemia.

Tsolakis AV, Portela-Gomes GM, Stridsberg M, Grimelius L, Sundin A, Eriksson BK, Oberg KE, Janson ET. Tsolakis AV, et al. Among authors: janson et. J Clin Endocrinol Metab. 2004 Aug;89(8):3739-44. doi: 10.1210/jc.2003-032118. J Clin Endocrinol Metab. 2004. PMID: 15292299

10

Treatment of endocrine pancreatic tumors.

Fjällskog ML, Janson ET. Fjällskog ML, et al. Among authors: janson et. Acta Oncol. 2005;44(4):329-38. doi: 10.1080/02841860510029941. Acta Oncol. 2005. PMID: 16120541 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page